Last reviewed · How we verify
NCT04103619
Energy-Based Lower Eyelid Rejuvenation - Proof of Concept for InMode AccuTite With or Without Morpheus8
NA trial testing AccuTite in Periorbital Edema in 12 participants. Completed in 13 December 2021.
13 December 2021
Quick facts
| Lead sponsor | InMode MD Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 16 May 2019 |
| Primary completion | 13 December 2021 |
| Estimated completion | 13 December 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- AccuTite
- AccuTite + Morpheus 8
Conditions studied
- Periorbital Edema — all drugs for Periorbital Edema →
Sponsor
InMode MD Ltd.
Who can join
Adults 29 to 75, any sex, with Periorbital Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. To establish clinical efficacy, safety and patient satisfaction of reducing lower eyelid convexities or "bags" and/or malar crescents (festoons) with catheter-based injectable RF (InMode AccuTite) and variable depth Fractional RF Microneedle skin rejuvenation (InMode Morpheus8). 2. To determine the relative effectiveness of dual-modality treatment (AccuTite + Morphues8 initial treatment followed by two consecutive Morpheus8 treatments 1 month apart) versus single modality treatment (AccuTite only)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025
Verify or expand the search:
- PubMed search for NCT04103619
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other InMode MD Ltd. trials
Trials by the same sponsor.
- NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
- NCT06283498 — Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder · NA · enrolling by invitation
- NCT06458556 — Transvaginal Radiofrequency Ablation for Overactive Bladder · NA · completed
- NCT05830968 — Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne · NA · recruiting
- NCT06283056 — RF Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04103619 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InMode MD Ltd.
- Last refreshed: 10 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04103619.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing